CAMBRIDGE, Mass – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed.
Scientific Publications
Neutrophil/Lymphocyte Ratio Prognostic in Melanoma
For patients with metastatic melanoma, neutrophil/lymphocyte ratio before initiating ipilimumab treatment is an independent prognostic indicator of poor survival, according to a study published online Sept. 6 in the British Journal of Dermatology.
Immune Irregularities May Increase Melanoma Risk Among Certain Non-Hodgkin’s Lymphoma Survivors
A collaborative team of interdisciplinary researchers led by Clara J.K. Lam, MPH, a predoctoral fellow in the Radiation Epidemiology Branch of the National Cancer Institute (NCI) and PhD student in cancer epidemiology at the George Washington University School of Public Health and Health Services, recently revealed study findings suggesting that immune irregularities may contribute to the high rates of melanoma observed in patients with non-hodgkins lymphoma (NHL) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The findings from the study entitled, “Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma,” were published in the latest edition of the Journal of Clinical Oncology the official journal of the American Society for Clinical Oncology.
Identifying protein that may predict response to PD-1 immunotherapy for melanoma
Mayo Clinic researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City.